160135-92-2

Usage

Uses

Treatment of hypertension and congestive heart failure (vasopeptidase inhibitor).

InChI:InChI=1/C19H26N2O4S/c1-19(2)10-6-9-14(18(25)21(19)12-16(22)23)20-17(24)15(26)11-13-7-4-3-5-8-13/h3-5,7-8,14-15,26H,6,9-12H2,1-2H3,(H,20,24)(H,22,23)/t14-,15?/m0/s1

Upstream product

• 76932-17-7 (S)-2-acetylthio-3-phenylpropanoic acid 
• 197902-92-4 (S)-2-phthalimido-6-methyl-6-hydroxyheptanoic acid, phenylmethyl ester 
• 182886-36-8 (S)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-6-oxo-heptanoic acid benzyl ester 
• 182886-83-5 (S)-hexahydro-7,7-dimethyl-3-<(triphenylmethyl)amino>-2H-azepin-2-one 
• 182886-39-1 (S)-hexahydro-6-phthalimido-2,2-dimethyl-2H-azepin-7-one 
• 182886-43-7 (S)-6-aminohexahydro-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid ethyl ester 
• 84688-14-2 benzyl (S)-2-(1,3-dioxoisoindolin-2-yl)-6-oxohexanoate 
• 84688-11-9 (S)-2-(1,3-dioxoisoindolin-2-yl)-6-hydroxyhexanoic acid 
• 229976-39-0 6-[[2-(acetylthio)-1-oxo-3-phenylpropyl]amino]hexahydro-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid 1,1-dimethylethyl ester 
• 606147-29-9 (S)-hexahydro-2,2-dimethyl-7-oxo-6-[(phenylmethoxy)carbonylamino]-1H-azepine-1-acetic acid 1,1-dimethylethyl ester 
• 606147-35-7 hexahydro-2,2-dimethyl-6-[[(1,1-dimethylethoxy)carbonyl]amino]-7-oxo-1H-azepine-1-acetic acid 1,1-dimethylethyl ester 
• 229976-43-6 (S)-6-aminohexahydro-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid 1,1-dimethylethyl ester 
• 606147-36-8 6-aminohexahydro-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid 1,1-dimethylethyl ester 
• 229976-40-3 6-[[2-(acetylthio)-1-oxo-3-phenylpropyl]amino]hexahydro-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid 

Relevant academic research and scientific papers

Efficient asymmetric synthesis of the vasopeptidase inhibitor BMS-189921

(Matrix presented) An efficient asymmetric synthesis of the vasopeptidase inhibitor BMS-189921 was accomplished. Two short enantioselective syntheses of the common key intermediate (S)-α-aminoazepinone 6b were developed. Olefin 3 was converted to 6b via a

Deprotection and recrystallization processes

Acylmercaptoalkanoylamino lactam esters or acids are converted to the corresponding mercaptoalkanoylamino lactam ester or acid under basic conditions by including an agent which minimizes the amount of disulfides. Suitable agents are bismercaptans, phosphine or phosphite reducing agents, zinc metal powder, and sodium hydrosulfite. Such agents are also employed in the recrystallization and reprocessing of the mercaptoalkanoylamino lactam acids.

Vasopeptidase inhibitors: Incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides

A series of 7-(di)alkyl and spirocyclic substituted azepinones were generated and incorporated as conformationally restricted dipeptide surrogates in mercaptoacyl dipeptides. Clear structure-activity relationships with respect to both angiotensin-converti

SUBSTITUTED AZEPINONE DUAL INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME AND NEUTRAL EXDOPEPTIDASE

Compounds of the formula STR1 are disclosed as possessing inhibitory activity against angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) and thus being useful as cardiovascular agents. Processes for preparing these compounds are also disclosed.